List of Atripla drug patents
Atripla is owned by Gilead Sciences.
Atripla contains Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate.
Atripla has a total of 7 drug patents out of which 0 drug patents have expired.
Atripla was authorised for market use on 12 July, 2006.
Atripla is available in tablet;oral dosage forms.
Atripla can be used as treatment of hiv infection, treatment of hiv-1 infection in pediatric patients 12 years of age and older; treatment of hiv-1 infection in adults, treatment of hiv-1 infection in adults; treatment of hiv-1 infection in pediatric patients 12 years of age and older.
The generics of Atripla are possible to be released after 28 April, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9744181 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(9 months from now) | |
| US8716264 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(9 months from now) | |
| US8592397 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(9 months from now) | |
| US9457036 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(9 months from now) | |
| US9545414 | GILEAD SCIENCES | Unitary pharmaceutical dosage form |
Jun, 2026
(3 years from now) | |
| US9018192 | GILEAD SCIENCES | Unitary pharmaceutical dosage form |
Jun, 2026
(3 years from now) | |
| US8598185 | GILEAD SCIENCES | Unitary pharmaceutical dosage form |
Apr, 2029
(6 years from now) | |
Drugs and Companies using EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 12 July, 2006
Treatment: Treatment of hiv infection; Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Treatment of hiv-1 infection in adults
Dosage: TABLET;ORAL
ATRIPLA family patents
29
United States
17
Japan
8
European Union
6
China
5
Australia
5
Argentina
4
Hong Kong
4
Norway
4
Korea, Republic of
4
Poland
4
Taiwan, Province of China
4
EA
4
Canada
3
Denmark
3
Slovenia
3
Croatia
3
Portugal
3
Cyprus
3
Spain
3
New Zealand
2
South Africa
2
Austria
2
Mexico
2
Germany
2
Brazil
2
Ukraine
1
Israel
1
Hungary
1
AP
1
Iceland
1
RS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic